Showing 1 - 3 results of 3 for search 'A. Lysén', query time: 0.02s Refine Results
  1. 1
    P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

    P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY by F. B. Askeland, E. Haukås, T. S. Slørdahl, D. Schjøll, A. Lysen, E. Hermansen, F. Schjesvold

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P938: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET)

    P938: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONP... by J. N. Nørgaard, N. Abildgaard, A. Lysén, G. Tsykunova, A. J. Vangsted, C. Joao, N. Remen, L. Osnes, J. P. Connelly, M.-E. R. Revheim, F. Schjesvold

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)

    P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT) by F. B. Askeland, A.-M. Rasmussen, A. Lysen, E. Haukås, A. Eilertsen, M. Moksnes, G. Tsykunova, A. Vik, B. D. Eiken, J. H. Sørbø, J. Rolke, K. O. Sand, R. F. Hallstensen, L. Myrseth, T. S. Slørdahl, F. Schjesvold

    Published 2022-06-01
    Get full text
    Article

Search Tools: